Prostaglandin E EP4 receptor antagonist - Eli LillyAlternative Names: EP4-R Antagonist - Eli Lilly
Latest Information Update: 07 Feb 2014
At a glance
- Originator Eli Lilly
- Class Small molecules
- Mechanism of Action Prostaglandin E EP4 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Musculoskeletal pain; Osteoarthritis
Most Recent Events
- 23 Jan 2014 Phase-I clinical trials in Musculoskeletal pain in USA (unspecified route)
- 23 Jan 2014 Phase-I clinical trials in Osteoarthritis in USA (unspecified route)